Lung mass pathophysiology: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) No edit summary |
Akshun Kalia (talk | contribs) |
||
| Line 23: | Line 23: | ||
==Gross Pathology== | ==Gross Pathology== | ||
[[File:Cancerous lung.jpg|left|thumb|250px|Cross section of a human lung. The white area in the upper lobe is cancer; the black areas indicate the patient was a smoker]] | |||
Revision as of 16:26, 28 February 2018
|
Lung Mass Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Lung mass pathophysiology On the Web |
|
American Roentgen Ray Society Images of Lung mass pathophysiology |
|
Risk calculators and risk factors for Lung mass pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief:
Overview
A lung mass is defined as an opacity in the lungs that is more than 3 cms (or 1 ½ inches) in size. Lung opacity less than 3 cms are classified as lung nodules.
Pathophysiology
Genetics
EGFR mutations are seen in about 20%- 50% of lung adenocarcinoma (especially in Asian population)
- EGFR mutations are responsible for the constitutive activation of the tyrosine kinase.
- The most frequent mutations are present in exons 18e21 of the EGFR gene.
- Other mutation involves translocations involving the anaplastic lymphoma kinase (ALK) tyrosine kinase are most frequently EML4-ALK fusions and are seen in estimated 10% of patients with lung adenocarcinoma.
- Genes involved in the pathogenesis of Non Small Cell Carcinoma (NSCC) include mutation in ROS1 gene.
- In Non Small Cell Carcinoma (NSCC), genetic translocations leads to activation of ROS1 gene.
- ROS1 is a receptor tyrosine kinase of the insulin receptor family.
- Other genes involved in pathogenesis of Non Small Cell Carcinoma (NSCC) include mutation in Her2 (ERBB2), BRAF mutations, MET and RET abnormalities.
Associated Conditions
Gross Pathology
